Prophylactic three-dimensional funnel mesh for prevention of parastomal hernia: propensity-score-matched cohort study Authors: Jacques-Emmanuel Saadoun, Eleftherios Gialamas, Alexandre Balaphas, Cécile de Chaisemartin, Hélène Meillat, Bernard Lelong, Christian Toso, Emilie Liot, Jérémy Meyer, Guillaume Meurette, Frédéric Ris Published: 2026 Parastomal hernia (PSH) is a frequent long-term complication following permanent end colostomy (PEC), with reported incidences up to 80%1. Beyond its incidence, PSH significantly impacts quality of life and remains difficult to treat, with high recurrence rates after repair. Preventive strategies are therefore essential, yet the optimal approach remains debated. Considering this problem, funnel-shaped three-dimensional (3D) meshes have emerged as a promising alternative, since Berger first described the technique2. This design stabilizes the bowel loop and reduces local tension. A retrospective study was undertaken comparing PSH incidence and postoperative complications after PEC with or without prophylactic funnel-shaped 3D mesh reinforcement (DynaMesh®-IPST; FEG-Textiltechnik, Aachen, Germany). Consecutive adult patients undergoing elective PEC in a tertiary referral centre between 2013 and 2024 were included. Procedures comprised extralevator abdominoperineal excision, low Hartmann procedure, Hartmann procedure, and pelvic exenteration for benign or malignant disease. Patients were divided according to prophylactic intraperitoneal 3D funnel mesh placement. Mesh use was not systematic and depended on progressive adoption, surgeon preference, and intraoperative considerations. Propensity score matching (1 : 1) was performed to reduce selection bias using clinically relevant variables, including age, sex, body mass index, American Society of Anesthesiologists score, neoadjuvant treatment, surgical approach, and type of procedure. After matching, 112 patients were analysed (56 per group; Fig. S1), with balanced baseline characteristics. PSH occurred in six patients in the IPST group, compared with 34 patients in the non-IPST group (11% versus 61%, respectively; P < 0.001; Table 1). Kaplan–Meier analysis demonstrated an early and sustained separation between groups, suggesting that a substantial proportion of PSH developed during the first year after surgery (Figs S2 and S3). Table 1Baseline characteristics, surgical variables, and postoperative outcomes before and after PSM in patients undergoing permanent end colostomy with or without prophylactic IPST meshBefore PSMAfter PSMNon-IPST (n = 97)IPST (n = 56) P* Non-IPST (n = 56)IPST (n = 56) P* Demographics Sex Male64 (66%)27 (48%)0.03134 (61%)27 (48%)0.200 Female33 (34%)29 (52%)22 (39%)29 (52%) Age (years), median (i.q.r.)69 (59–77)70 (58–75)0.800†70 (62–78)70 (58–75)0.500† ASA grade0.2000.300 I–II37 (38%)27 (48%)22 (39%)27 (48%) III–IV60 (62%)29 (52%)34 (61%)29 (52%) BMI (kg/m2), median (i.q.r.)25.3 (22–28)24.8 (22–27)0.400†24.7 (22–28)24.8 (22–27)0.900† Smoker42 (43%)27 (48%)0.60024 (43%)27 (48%)0.600 Active smoker25 (26%)20 (36%)0.20014 (25%)20 (36%)0.200 Co-morbidity Hypertension38 (39%)29 (52%)0.13024 (43%)29 (52%)0.300 Cardiovascular13 (13%)10 (18%)0.50011 (20%)10 (18%)0.800 Diabetes20 (21%)10 (18%)0.70012 (21%)10 (18%)0.600 Chronic renal disease13 (13%)7 (13%)0.9009 (16%)7 (13%)0.600 Cirrhosis9 (9%)3 (5%)0.500‡5 (9%)3 (5%)0.700‡ COPD6 (6%)5 (9%)0.500‡5 (9%)5 (9%)> 0.900‡ Previous abdominal surgery41 (42%)26 (46%)0.60024 (43%)26 (46%)0.700 Surgical indication0.140‡0.700‡ Adenocarcinoma67 (69%)44 (80%)45 (80%)42 (75%) Squamous cell carcinoma6 (6%)6 (11%)4 (7%)5 (9%) Diverticular disease7 (7%)2 (4%)3 (6%)2 (4%) Genitourinary cancer6 (6%)0 (0%)1 (2%)4 (7%) Others11 (11%)3 (5%)3 (6%)3 (5%) Neoadjuvant therapy53 (55%)40 (71%)0.04037 (66%)40 (71%)0.500 Irradiation48 (49%)39 (70%)0.01534 (61%)39 (70%)0.300 Surgery characteristics Surgical procedure< 0.0010.500 ELAPE36 (37%)39 (70%)32 (57%)39 (70%) Low Hartmann31 (32%)8 (14%)12 (21%)8 (14%) Hartmann16 (17%)2 (3%)4 (7%)2 (3%) Pelvic exenteration14 (14%)7 (13%)8 (14%)7 (13%) Surgical approach< 0.0010.900 Open43 (44%)9 (16%)12 (21%)9 (16%) Laparoscopic51 (53%)44 (79%)41 (73%)44 (79%) Robot3 (3%)3 (5%)3 (5%)3 (5%) Postoperative outcomes within 90 days Clavien–Dindo complications0.2000.300 Grade I6 (6%)2 (4%)3 (5%)2 (4%) Grade II35 (36%)19 (34%)26 (46%)20 (36%) Grade III12 (13%)15 (27%)5 (9%)13 (23%) Grade IV2 (2%)1 (2%)1 (2%)1 (2%) Reintervention8 (8%)16 (29%)< 0.0014 (7%)16 (29%)0.003 Main outcome and follow-up PSH56 (58%)6 (11%)< 0.00134 (61%)6 (11%)< 0.001 Time to PSH occurrence (days), median (i.q.r.)373 (220–737)886 (475–1069)0.120†466 (253–778)886 (475–1069)0.200†Values are n (%) unless otherwise stated. PSM, propensity score matching; IPST, DynaMesh®-IPST (FEG-Textiltechnik, Aachen, Germany). i.q.r., interquartile range; ASA, American Society of Anesthesiologists; BMI, body mass index; COPD, chronic obstructive pulmonary disease; ELAPE, extralevator abdominoperineal excision; PSH, parastomal hernia. *Pearson’s χ2 test, except †Wilcoxon rank sum test and ‡Fisher’s exact test. Baseline characteristics, surgical variables, and postoperative outcomes before and after PSM in patients undergoing permanent end colostomy with or without prophylactic IPST mesh Values are n (%) unless otherwise stated. PSM, propensity score matching; IPST, DynaMesh®-IPST (FEG-Textiltechnik, Aachen, Germany). i.q.r., interquartile range; ASA, American Society of Anesthesiologists; BMI, body mass index; COPD, chronic obstructive pulmonary disease; ELAPE, extralevator abdominoperineal excision; PSH, parastomal hernia. *Pearson’s χ2 test, except †Wilcoxon rank sum test and ‡Fisher’s exact test. Overall postoperative morbidity did not differ between groups, and no mesh-related complications were observed. However, reintervention rates were higher in the IPST than non-IPST group (29% versus 7%; P = 0.003), mainly driven by perineal wound dehiscence. This difference may reflect residual confounding despite matching, particularly the higher proportion of extralevator procedures and pelvic irradiation, both of which are recognized risk factors for perineal morbidity. Previous randomized trials evaluating prophylactic mesh in PEC have reported conflicting results, particularly with retrorectus techniques3,4. More recently, a randomized trial evaluating funnel-shaped intraperitoneal mesh demonstrated a significant reduction in PSH without increased morbidity5. The findings of the present study are consistent with these data and support the potential benefit of this approach in routine practice. However, the non-systematic use of mesh in the present cohort reflects real-world decision-making and introduces an inherent selection bias. In this context, the results reinforce the need to better define which patients may derive the greatest benefit from prophylactic mesh placement. Long-term safety of intraperitoneal mesh remains an important consideration, particularly in oncological patients. In the present cohort, no mesh-related complications were identified during follow-up. This study has several limitations. The retrospective design and non-systematic use of mesh introduce an inherent selection bias, limiting causal inference, although propensity score matching was used to mitigate this effect. In addition, this was a single-centre study, which may limit generalizability. Prophylactic IPST mesh placement was associated with a marked reduction in PSH rates after PEC, without increased overall postoperative morbidity. These findings support a potential role while highlighting the need for careful patient selection. Further prospective studies are needed to confirm these results and better define optimal indications. Supplementary Material Contributor Information Jacques-Emmanuel Saadoun, Division of Digestive Surgery, University Hospitals of Geneva, Geneva, Switzerland; Department of Digestive and Surgical Oncology, Institut Paoli-Calmettes, Marseille, France. Eleftherios Gialamas, Division of Digestive Surgery, University Hospitals of Geneva, Geneva, Switzerland; Medical School, University of Geneva, Geneva, Switzerland. Alexandre Balaphas, Division of Digestive Surgery, University Hospitals of Geneva, Geneva, Switzerland; Medical School, University of Geneva, Geneva, Switzerland. Cécile de Chaisemartin, Department of Digestive and Surgical Oncology, Institut Paoli-Calmettes, Marseille, France. Hélène Meillat, Department of Digestive and Surgical Oncology, Institut Paoli-Calmettes, Marseille, France. Bernard Lelong, Department of Digestive and Surgical Oncology, Institut Paoli-Calmettes, Marseille, France. Christian Toso, Division of Digestive Surgery, University Hospitals of Geneva, Geneva, Switzerland; Medical School, University of Geneva, Geneva, Switzerland. Emilie Liot, Division of Digestive Surgery, University Hospitals of Geneva, Geneva, Switzerland; Medical School, University of Geneva, Geneva, Switzerland. Jérémy Meyer, Division of Digestive Surgery, University Hospitals of Geneva, Geneva, Switzerland; Medical School, University of Geneva, Geneva, Switzerland. Guillaume Meurette, Division of Digestive Surgery, University Hospitals of Geneva, Geneva, Switzerland; Medical School, University of Geneva, Geneva, Switzerland. Frédéric Ris, Division of Digestive Surgery, University Hospitals of Geneva, Geneva, Switzerland; Medical School, University of Geneva, Geneva, Switzerland. Funding The authors have no funding to declare. Author contributions Jacques-Emmanuel Saadoun (Conceptualization, Data curation, Formal analysis, Methodology, Writing—original draft, Writing—review & editing), Eleftherios Gialamas (Conceptualization, Supervision, Writing—original draft, Writing—review & editing), Alexandre Balaphas (Conceptualization, Writing—original draft, Writing—review & editing), Cecile De Chaisemartin (Conceptualization, Visualization, Writing—review & editing), Helene Meillat (Conceptualization, Formal analysis, Writing—original draft, Writing—review & editing), Bernard Lelong (Conceptualization, Writing—original draft, Writing—review & editing), Christian Toso (Conceptualization, Data curation, Supervision, Writing—original draft, Writing—review & editing), Emilie Liot (Conceptualization, Methodology, Writing—review & editing), Jeremy Meyer (Conceptualization, Supervision, Writing—review & editing), Guillaume Meurette (Conceptualization, Methodology, Supervision, Writing—review & editing), and Frédéric Ris (Conceptualization, Data curation, Methodology, Supervision, Writing—original draft, Writing—review & editing) Disclosure The authors declare no conflict of interest. Supplementary material Supplementary material is available at BJS Open online. Data availability The data underlying this article will be shared upon reasonable request to the corresponding author. References Associated Data Supplementary Materials Data Availability Statement The data underlying this article will be shared upon reasonable request to the corresponding author.